The typical time frame for observing a response to BCG therapy in NMIBC patients is within 3 to 6 months following initiation. While many patients initially respond well, a substantial ...

MONDAY, May 12, 2025 (HealthDay News) — Bacille Calmette-Guérin (BCG) revaccination is not efficacious for preventing sustained Mycobacterium tuberculosis infection, defined by sustained ...

Some CEOs are asking when they'll make money from AI, BCG's Sylvain Duranton told Business Insider. He said the biggest factor in succeeding with AI isn't the tech, but changing how people work.

India for the World, a leadership podcast series presented by Mint and the Boston Consulting Group (BCG), has just launched its debut episode, spotlighting a topic critical to India’s financial ...

We'd like you to think beyond the obvious, and surprise us with material that is inventive and hilarious. There are lots of resources on BCG Pro to help you, and we look forward to reading your work.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial. Treatment with the combination of durvalumab (Imfinzi) and ...

Durvalumab plus BCG therapy significantly improved DFS in high-risk NMIBC compared to BCG alone, with no detriment in overall survival. The phase 3 POTOMAC trial involved 1018 patients across 12 ...

Motivated to clear the misconception of climate projects being complex and nascent, lead author Daniel Oehling, a managing director and partner at BCG’s Singapore office, said the report laid out the ...

Bacille Calmette-Guérin (BCG) revaccination didn't help prevent sustained Mycobacterium tuberculosis infection in initially uninfected adolescents without HIV in a randomized trial from South Africa.

Helen Lederer has been involved in comedy creation since the 1970s. We talk to her following her appearance on Pilgrimage: The Road Through the Alps and as she prepares to appear in the Fawlty Towers ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application for Anktiva in patients with BCG-unresponsive non-muscle invasive bladder ...